Knowing a companies pipeline of drug candidates, might give us a view of future products of commercialization, should everything work out favorable in clinical trials. With the 4th quarter of 2023 almost completed, a check on the pipeline of Axsome Therapeutics heading into 2024, is below.
The important readout will the AXS-05 phase 3, Alzheimer's Agitation clinical trial, to be completed in the first half of 2024. Another notable readout, will be the Solriamfetol phase 3 for Attention Deficit Hyperactivity Disorder (ADHD), scheduled in the second half of 2024. Thank you for reading.
